Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy

Darunavir/ritonavir monotherapy maintains HIV suppression in most patients who have achieved an undetectable viral load on combination antiretroviral treatment, and is increasingly used in the clinic. However, concerns have been raised about the effectiveness of ritonavir-boosted protease inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Gisslén, Magnus, Fuchs, Dietmar, Hagberg, Lars, Svennerholm, Bo, Zetterberg, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2012
Materias:
Case-Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507278/
https://www.ncbi.nlm.nih.gov/pubmed/22776013
http://dx.doi.org/10.3109/00365548.2012.690526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507278/
https://www.ncbi.nlm.nih.gov/pubmed/22776013
http://dx.doi.org/10.3109/00365548.2012.690526

Ejemplares similares